JAK/TYK2
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr.
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 3 months ago
⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF
Dr. John Cush RheumNow
4 years 3 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.
Janet Pope Janetbirdope
4 years 3 months ago
JAKi to #JAKi cycling is common in #rheumatoidarthritis Rx. Opal registry >53000 pts, 1/4 treated with JAKi (4000) & 44% new starts were Jaki. JAKi to JAKi cycling was >40%! POS0223 #EULAR2021 @RheumNow https://t.co/XV7wVJsE9c
RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed
Dr. John Cush RheumNow
4 years 3 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.
Paul Studenic Stiddyo
4 years 3 months ago
#OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16weeks
Primary endpoint ACR20
12mg: 62.7%
6mg: 52.9%
PLC: 31.8%
+ well tolarated: no serious adverse events
#EULAR2021 @RheumNow https://t.co/6SFqWd79db
Janet Pope Janetbirdope
4 years 3 months ago
Ever wonder why one drug works in a pt & not another? Study of bio markers in PsA from RCT of #upadacitinib vs #adalimumab shows diff pathways affected by each drug & some overlap too @RheumNow #EULAR2021 @eular_org OP0030 https://t.co/WifrVOIMkW
Janet Pope Janetbirdope
4 years 3 months ago
Can machine learning show JAKi effects for safety? Off target binding predicted in #tofacitinib 58, #baricitinib 41 but NO pathway for thrombosis or viral infection. Could have repurposing for + effects on lung vasculature & antifibrotic effects POS0091 #EULAR2021 @RheumNow
Janet Pope Janetbirdope
4 years 3 months ago
MACE events with #JAKi is as clear as mud! You voted >50% NOT Sure 1/3 only some Jakis vs MACE in #TNFi! Dunno #EULAR2021 @RheumNow @eular_org https://t.co/vWUgKSwAap
Janet Pope Janetbirdope
4 years 3 months ago
Poorer outcomes with #JAKi in pts who get #SARSCoV2 but ? related to line of therapy - worse off if 2nd line advanced Rx in RA vs 1st line? JAKi has short half life so it washes out? And..#baricitinib added to #remdesivir improves outcomes NEJM @RheumNow #EULAR2021 #OP0006 Dunno! https://t.co/583z6Mlw3y
Robert B Chao, MD doctorRBC
4 years 3 months ago
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD
⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD
⭐️No overall increase in all CA: RTX, TOCI
⭐️Abatacept 1.21HR for all cancer, mainly NMSC
⭐️needs more data on JAKs, IL-17, IL-23
Abs#6916
#EULAR2021 @RheumNow
Poster Hall